· Periodic Report
Q3 operating loss of KRW 19.9 billion on revenue of KRW 8.8 billion
ABL Bio earned KRW 8.8 billion from operations in Q3 and lost KRW 19.9 billion from its main business, with KRW 41.6 billion earned from January to September.
298380 · KOSDAQ · Based on DART filings
1 total · 20 per page
· Periodic Report
ABL Bio earned KRW 8.8 billion from operations in Q3 and lost KRW 19.9 billion from its main business, with KRW 41.6 billion earned from January to September.
Get app alerts for new disclosures from ABL Bio Inc..